Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saul N Faust

Showing results (121-130 of 225) with videos related to

Pageof 23
Sort By:
BMJ (Clinical Research Ed.)|April 3, 2015
Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trialDavid Pace, Ameneh Khatami, Jennifer McKenna, et al.
The European Respiratory Journal|September 12, 2017
Primary ciliary dyskinesia ciliated airway cells show increased susceptibility to <i>Haemophilus influenzae</i> biofilm formationWoolf T Walker, Claire L Jackson, Raymond N Allan, et al.
Health Technology Assessment (Winchester, England)|November 5, 2021
Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCTSam Barratt, Julia A Bielicki, David Dunn, et al.
Antimicrobial Agents and Chemotherapy|February 10, 2016
Low Concentrations of Nitric Oxide Modulate Streptococcus pneumoniae Biofilm Metabolism and Antibiotic ToleranceRaymond N Allan, Samantha Morgan, Sanjita Brito-Mutunayagam, et al.
BMJ Open|January 26, 2022
Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (BATCH): protocol for a randomised controlled trialCherry-Ann Waldron, Emma Thomas-Jones, Jolanta Bernatoniene, et al.
Frontiers in Medical Technology|January 20, 2022
Powered Respirators Are Effective, Sustainable, and Cost-Effective Personal Protective Equipment for SARS-CoV-2Alasdair Munro, Jacqui Prieto, Emmanouil Mentzakis, et al.
Pediatrics|August 10, 2016
Schedules for Pneumococcal Vaccination of Preterm Infants: An RCTAlison Kent, Shamez N Ladhani, Nick J Andrews, et al.
The Lancet. Microbe|December 3, 2022
Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trialAdam P Dale, Anastasia A Theodosiou, Diane F Gbesemete, et al.
The Pediatric Infectious Disease Journal|January 26, 2013
Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infantsAmeneh Khatami, Matthew D Snape, Brigitte Ohene-Kena, et al.
The Lancet. Infectious Diseases|September 16, 2022
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, An Vandebosch, Jerald Sadoff, et al.
Pageof 23

Showing results (121-130 of 225) with videos related to

Sort By:
Pageof 23
BMJ (Clinical Research Ed.)|April 3, 2015
Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trialDavid Pace, Ameneh Khatami, Jennifer McKenna, et al.
The European Respiratory Journal|September 12, 2017
Primary ciliary dyskinesia ciliated airway cells show increased susceptibility to <i>Haemophilus influenzae</i> biofilm formationWoolf T Walker, Claire L Jackson, Raymond N Allan, et al.
Health Technology Assessment (Winchester, England)|November 5, 2021
Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCTSam Barratt, Julia A Bielicki, David Dunn, et al.
Antimicrobial Agents and Chemotherapy|February 10, 2016
Low Concentrations of Nitric Oxide Modulate Streptococcus pneumoniae Biofilm Metabolism and Antibiotic ToleranceRaymond N Allan, Samantha Morgan, Sanjita Brito-Mutunayagam, et al.
BMJ Open|January 26, 2022
Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (BATCH): protocol for a randomised controlled trialCherry-Ann Waldron, Emma Thomas-Jones, Jolanta Bernatoniene, et al.
Frontiers in Medical Technology|January 20, 2022
Powered Respirators Are Effective, Sustainable, and Cost-Effective Personal Protective Equipment for SARS-CoV-2Alasdair Munro, Jacqui Prieto, Emmanouil Mentzakis, et al.
Pediatrics|August 10, 2016
Schedules for Pneumococcal Vaccination of Preterm Infants: An RCTAlison Kent, Shamez N Ladhani, Nick J Andrews, et al.
The Lancet. Microbe|December 3, 2022
Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trialAdam P Dale, Anastasia A Theodosiou, Diane F Gbesemete, et al.
The Pediatric Infectious Disease Journal|January 26, 2013
Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infantsAmeneh Khatami, Matthew D Snape, Brigitte Ohene-Kena, et al.
The Lancet. Infectious Diseases|September 16, 2022
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, An Vandebosch, Jerald Sadoff, et al.
Pageof 23